gm102
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2016 (NCT02978755)
Timeline
Indications
Mechanism of action
AMHR2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- gm102
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03799731 | Phase 2 | Jul 11, 2018 | GamaMabs Pharma, Katholieke Universiteit Leuven |
| NCT02978755 | Phase 1 | Jun 1, 2016 | GamaMabs Pharma |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GamaMabs Pharma | For profit | 2 | 2 | 2 | 2016 |
| Katholieke Universiteit Leuven | Academic/Hospital | 1 | 0 | 1 | 2018 |
2 organizations
Page 1 / 1